Rapid7 Q1 ARR Slightly Beats Guide, Stabilization Narrative Gains Traction

What happened

Rapid7 reported Q1 2026 ARR of $832 million, slightly above the guided ~$830 million, with total revenue of $210 million and non-GAAP operating income of $24 million. Free cash flow came in at $33 million, consistent with the full-year guidance range of $125–$135 million on an annualized run-rate basis. The results provide the first measurable evidence that the go-to-market reset is stabilizing ARR, as the metric did not slip below the Q1 baseline feared by bears. However, ARR remains down from the prior year's ~$840 million exit rate, and the company continues to face headwinds from legacy vulnerability management churn. The sequential ARR improvement supports the base-case scenario from the DeepValue report, but sustained execution through Q2 and Q3 remains critical to confirm the turnaround.

Implication

The Q1 results modestly de-risk the investment thesis, as ARR stabilization is on track. The guided FCF range appears achievable, supporting the equity's self-help narrative. However, given elevated net debt and competitive pressures, conviction should increase only if Q2'26 ARR exceeds $832 million and management reiterates full-year FCF guidance. The stock's low valuation prices in considerable skepticism, so a string of beats could drive a re-rating.

Thesis delta

The slight ARR beat shifts the near-term outlook from the bear case (ARR ≤$830M through Q3) toward the base case (sequential improvement), reducing the probability of a capital impairment event. However, the overarching risk of legacy churn and balance sheet leverage remains, so the thesis is now more balanced but still requires multi-quarter proof.